Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II of Immunotherapy Plus Local Tumor Ablation in Colorectal Cancer Liver Metastases
NCT03101475Phase 2Completed
- Sponsor
- European Organisation for Research and Treatment of Cancer
- Start
- Nov 2018
- Primary completion
- Mar 2021
- Modality
- Antibody Conjugates, Engineered Antibody Formats, PD-1/PD-L1 Inhibitors
- Countries
- 6
01
Overview
A Phase 2 trial of durvalumab, tremelimumab in colorectal cancer (CRC), sponsored by European Organisation for Research and Treatment of Cancer. Started Nov 2018; status: completed.
02
Drugs
durvalumabtremelimumab
03
Conditions
colorectal cancer (CRC)
Beyond the preview
Go deeper on NCT03101475.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03101475.